Search Results
Your search for ,maY matches 16456 pages
Showing 2501 - 2550Half of Patients With Cancer May Develop Long COVID, With Risk Higher in Female Patients
More than one in two patients with cancer may experience symptoms of long COVID for more than 6 months after initial COVID-19 infection, according to a new study published by Dagher et al in eLife. The findings were comparable to the reported incidence of long COVID in the general population, but...
Higher Rate of Clonal Hematopoiesis in Pediatric Cancer Survivors May Be Linked With Treatment-Induced STAT3 Gene Mutations and Risk of Adverse Long-Term Outcomes
Studies show that although clonal hematopoiesis is an age-related phenomenon in the general population, it can also be induced by exposure to chemotherapy, which can affect both the emergence and evolution of clonal hematopoiesis clones, accelerating aging at both the physiologic and molecular...
Methotrexate May Be Associated With an Increased Risk for Some Skin Cancers
Methotrexate may be linked to an elevated risk of three types of skin cancer, according to a new study published by Polesie et al in the British Journal of Cancer. Additionally, among patients taking the drug to treat moderate to severe psoriasis, an increased risk was observed only for basal cell...
Lung Cancer Screening May Be More Cost-Effective When Using Risk Model–Based Strategies
Risk model–based lung cancer screening strategies may be more cost-effective than current recommendations that are based solely on the patient’s age and smoking history, according to a new study published by Toumazis et al in the Annals of Internal Medicine. The findings also suggested that...
What Can Be Learned From Negative Findings of Two Trials in Biliary Tract Cancer
Biliary tract cancer is particularly difficult to treat, with a median overall survival of about 1 year with standard-of-care gemcitabine-based regimens. Advanced biliary tract cancer is an area of significant unmet need because of its aggressive nature, limited treatment options, and poor...
SBRT for Patients With Primary Lung Neuroendocrine Tumors
Researchers have found that stereotactic body radiotherapy (SBRT) may be an effective treatment for patients with early-stage lung neuroendocrine tumors, according to a new study published by Oliver et al in the International Journal of Radiation Oncology • Biology • Physics. Background Primary...
Defensive Beliefs May Prevent Individuals From Partaking in Screening for Colorectal Cancer
Investigators have revealed that individuals who react defensively to an invitation for colorectal cancer screening may be less likely to take part, according to a new study published by Clarke et al in Cancer. Background Colorectal cancer is one of the most treatable cancer types—especially if...
Researchers Uncover Racial and Ethnic Disparities in Widely Used Precision Oncology Data Registry
Biorepositories created to support precision cancer research through their vast stores of genomic data may lack sufficient representation of cancer distribution among racial and ethnic minorities, according to a new study published by Cheung et al in npj Precision Oncology. The investigators also...
Preclinical Study Shows Losartan May Prevent Immune Checkpoint Inhibitor–Induced Cerebral Edema in Glioblastoma
Researchers revealed that the blood pressure drug losartan may prevent immunotherapy-induced edema and allow patients with glioblastoma to continue receiving immune checkpoint inhibitors without developing adverse effects in the brain, according to a new study published by Datta et al in...
Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer in Survivors of Hodgkin Lymphoma
In a Dutch study reported in JAMA Oncology, Geurts et al found a dose-response relationship between radiotherapy and risk of colorectal cancer among survivors of Hodgkin lymphoma, with the risk being increased with increasing procarbazine dose. Study Details The nested case-control study included...
Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer and High FRα Expression
As reported in the Journal of Clinical Oncology by Ursula A. Matulonis, MD, and colleagues, results from the phase II SORAYA study showed activity of mirvetuximab soravtansine-gynx, an antibody-drug conjugate targeting folate receptor alpha (FRα), in patients with platinum-resistant ovarian cancer...
Challenges of Accurately Identifying HER2-Low Breast Cancers
The newly identified category of “HER2-low” breast cancer has raised many new issues in this malignancy now that the DESTINY Breast-041 trial determined that fam-trastuzumab deruxtecan-nxki (T-DXd) may effectively treat this tumor. Among the issues are challenges in accurately identifying just...
Massage Therapy May Improve Symptom Burden for Pediatric Patients With Hematologic and/or Oncologic Conditions
A new study from University Hospitals (UH) Connor Whole Health found children, adolescents, and young adults with cancer or sickle cell disease treated at a pediatric academic medical center reported clinically significant reductions in pain, stress, and anxiety in response to massage therapy....
World Cancer Day: Commercial Interests May Drive Millions of Avoidable Cancer Deaths
The Union for International Cancer Control (UICC)—in light of World Cancer Day, taking place on February 4—has called on governments around the world to prioritize policy actions to reduce preventable cancers caused by tobacco use and the consumption of alcohol and ultraprocessed foods, including...
Researchers Develop AI Algorithm to Gain New Insights Into Glioblastoma
Researchers have developed an artificial intelligence (AI) algorithm, known as SPHINKS, capable of performing advanced computational analyses to identify potential therapeutic targets for patients with glioblastoma multiforme. The platform may also have applicability in other cancers, according to...
Ponatinib and Blinatumomab Combination Safe and Effective in Patients With Newly Diagnosed, Ph-Positive ALL
The combination of ponatinib and blinatumomab has led to rapid and durable remissions in patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and...
Review Provides Recommendations on Cancer Treatment in the Context of Preexisting Dementia
According to a review published by Ashley et al in CA: A Cancer Journal for Clinicians, preexisting dementia may complicate cancer care and increase the risk of worse clinical outcome and inferior patient experience. People living with dementia are more likely to have cancer diagnosed at an...
Neoadjuvant Plus Adjuvant Chemotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Colon Cancer
As reported in the Journal of Clinical Oncology by Morton et al, the European phase III FOxTROT trial has shown that neoadjuvant plus adjuvant oxaliplatin/fluoropyrimidine resulted in a reduced risk of residual disease or disease recurrence vs adjuvant oxaliplatin/fluoropyrimidine in patients with...
Surgical Quality Metric Scoring and Survival Among U.S. Veterans With Early-Stage NSCLC
In a study reported in JAMA Surgery, Heiden et al developed a surgical quality metric scoring system—the Veterans Affairs Lung Cancer Operative quality (VALCAN-O) score—that was associated with overall survival in U.S. veterans undergoing curative-intent surgery for early-stage non–small cell lung...
Consuming Ultraprocessed Foods May Be Linked to Increased Cancer Risk and Mortality
Higher consumption of ultraprocessed foods may be linked to increased cancer burden and mortality, according to a new, UK-based study published by Chang et al in eClinicalMedicine. Ultraprocessed foods are food items which have been heavily processed during their production—such as fizzy drinks,...
Adjuvant Osimertinib Significantly Improves Disease-Free Survival for Patients With Resected EGFR-Mutant NSCLC
The EGFR tyrosine kinase inhibitor osimertinib may improve rates of disease-free survival and reduce the risk of recurrence in patients with resected, EGFR-mutant non–small cell lung cancer (NSCLC), according to a new exploratory analysis of the ADAURA trial published by Roy S. Herbst, MD, PhD,...
Addition of Anti–IGF-1R Antibody Ganitumab to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Metastatic Ewing Sarcoma
As reported in the Journal of Clinical Oncology by DuBois et al, the Children’s Oncology Group phase III AEWS1221 trial showed no event-free survival benefit with the addition of the anti–insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody ganitumab to interval-compressed...
Levels of Inflammatory Biomarkers and Survival in Patients Receiving Adjuvant Therapy for Stage III Colon Cancer
In a study reported in JAMA Oncology, Cheng et al found that higher levels of inflammatory biomarkers measured after surgery—but before receipt of chemotherapy—were associated with poorer outcomes in patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 trial of adjuvant...
Study Finds Breast MRI Superior vs Other Supplementary Screening Tests for Detecting Breast Cancer in Patients With Dense Breasts
Compared to other common supplemental screening methods, breast magnetic resonance imaging (MRI) was superior at detecting breast cancer in patients with dense breasts, according to a new study published by Hussein et al in Radiology. Background Breast cancer is one of the leading causes of cancer...
Gap Discovered in Breast Cancer Radiotherapy Recommendations for Patients Aged 70 vs 69 Years
Age-based heuristics may lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new study published by Talcott et al in the International Journal of Radiation Oncology • Biology • and Physics. Background Radiation therapy often is given...
Genomic Screening May Help Detect Medullary Thyroid Cancer, Study Finds
Population-based genomic screening may facilitate early detection of medullary thyroid cancer in patients with variants in the RET gene, according to a new study published by Pichardo et al in JAMA Otolaryngology–Head & Neck Surgery. Background Medullary thyroid cancer accounts for 2% to 5% of...
Momelotinib May Effectively Reduce Anemia and Other Symptoms for Patients With Myelofibrosis
The targeted therapy momelotinib may offer clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, for patients with myelofibrosis, according to a novel study published by Srdan Verstovsek, MD, PhD, and colleagues in The Lancet. The findings support...
Immunotherapy Combined With Targeted Therapy in Patients With BRAF V600E–Mutated Colorectal Cancer
In one of the first clinical trials combining immunotherapy and targeted therapy for patients with BRAF V600E–mutated colorectal cancer, researchers discovered that a combination regimen of dabrafenib, trametinib, and spartalizumab resulted in long-lasting responses. The study findings published by ...
Laura A. Dawson, MD, on Hepatocellular Carcinoma: Phase III Data on Sorafenib vs Stereotactic Body Radiation Therapy
Laura A. Dawson, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings from the NRG/RTOG1112 study, which showed that stereotactic body radiation therapy (SBRT) administered prior to sorafenib vs sorafenib alone, improved outcomes in patients with advanced hepatocellular...
Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation
In a study reported in JAMA Oncology, McDonald et al found that receipt of blood or marrow transplantation (BMT) was associated with an increased risk of subsequent malignant neoplasms of the gastrointestinal (GI) tract. As stated by the investigators, “Survivors of BMT are at increased risk of...
New Analysis Sheds Light on Potential Link Between Ovulation and Ovarian Cancer
Individuals who ovulate for longer over their lifetimes may have a higher risk of developing ovarian cancer, suggesting that suppressing ovulation can lower this risk, according to a new study published by Fu et al in the Journal of the National Cancer Institute. The researchers also offered clues...
New Study Shows Increased Cancer Mortality Among Patients With Type 2 Diabetes in England
New research shows that patients with type 2 diabetes may experience a substantially higher rate of cancer mortality than the general population—by 18% for all cancers combined, 9% for breast cancer, and as much as 2.4-fold for colorectal cancer—according to a new study published by Ling et al in...
Julien Taïeb, MD, PhD, on Treating Colorectal Cancer With Trifluridine and Tipiracil Plus Bevacizumab
Julien Taïeb, MD, PhD, of Hôpital Européen Georges Pompidou, Université Paris-Cité, discusses the clinical implications of new phase III findings from the SUNLIGHT study, which showed that trifluridine and tipiracil (FTD/TPI) plus bevacizumab resulted in improved outcomes compared with FTD/TPI...
ctDNA Analysis May Predict Optimal Treatment for Patients With GIST
Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented by Bauer et al during the January ASCO Plenary Series session (Abstract 397784). An...
Analysis of Mutations Associated With High Tumor Mutation Burden in Microsatellite-Stable Gastrointestinal Cancers
In a study reported in The Lancet Oncology, Wang et al identified mutations linked to high tumor mutation burden in microsatellite-stable (MSS) gastrointestinal cancers that may be associated with efficacy of immune checkpoint inhibitor therapy. Study Details Molecular alterations in 48,606...
Updated Results of DESTINY-Breast03: T-DXd vs T-DM1 for Previously Treated Patients With HER2-Positive Metastatic Breast Cancer
As reported in The Lancet by Sara A. Hurvitz, MD, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or...
Receiving Chemotherapy in the Afternoon May Improve Treatment Outcomes in Some Patients With DLBCL
Utilizing chronochemotherapy—a method aimed at delivering chemotherapy at a time when the body is least vulnerable to its harmful effects and when the cancer cells are at their most vulnerable—may improve the outcomes of some patients with diffuse large B-cell lymphoma (DLBCL), according to a novel ...
Emily C. Daugherty, MD, on FLASH Radiotherapy: Efficacy and Safety Results From the First-in-Human Study
Emily C. Daugherty, MD, of the University of Cincinnati, discusses results from the FAST-01 study, which showed that FLASH proton radiotherapy, delivered at ultra-high–dose rates, may be efficacious, with adverse events comparable to conventional dose-rate treatment of patients with cancer....
Undaunted
Soon after my marriage, in 2003, I noticed swelling in the glands around my throat. Although I otherwise felt fine, I went to see my primary care physician for a checkup and a blood test. The results of the test showed that I had an abnormally high number of lymphocytes circulating in my...
Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care
Most of us have felt our stomachs sink as we opened a patient’s radiology or laboratory report and realized the patient faced a grave situation. If we’re lucky, we have a couple of days before a scheduled patient appointment to prepare ourselves to deliver that bad news. Other times, we may have...
Inaugural Recipients of the Lubin Family Foundation Scholar Award Named
The four inaugural recipients of the Lubin Family Foundation Scholar Award have been announced by Dana-Farber Cancer Institute and the Richard K. Lubin Family Foundation. Lubin Scholars are among the most promising physician-scientists pursuing cancer-relevant basic or translational...
Expert Point of View: Nancy Chan, MD
Nancy Chan, MD, Director of Breast Cancer Clinical Research at NYU Langone’s Perlmutter Cancer Center, New York, commented on the monarchE analysis for The ASCO Post. She noted that the study investigated the addition of adjuvant abemaciclib (an oral CDK4/6 inhibitor) to endocrine therapy in a...
Expert Point of View: Jaime A. Suarez-Londono, MD
Jaime A. Suarez-Londono, MD, a medical oncologist at NYU Langone’s Perlmutter Cancer Center and Assistant Professor of Medicine at NYU Grossman School of Medicine, said the results of the ASAP study provide a basis for discussion with the transplant team. “The landscape of treatment of acute...
Intensive Remission Induction Chemotherapy vs Less Intensive Approach Prior to Transplant for Relapsed/Refractory AML
Intensive salvage therapy with the goal of achieving complete remission prior to allogeneic hematopoietic cell transplantation (alloHCT) may not be necessary in some patients with relapsed or refractory acute myeloid leukemia (AML), according to the results of the phase III ASAP trial presented at...
Andrea Schietinger, PhD, to Present 2023 AACR–Irving Weinstein Foundation Distinguished Lecture
The American Association for Cancer Research (AACR) will award the 19th AACR–Irving Weinstein Foundation Distinguished Lectureship to Andrea Schietinger, PhD, during the 2023 AACR Annual Meeting, held April 14–19, in Orlando, Florida. Dr. Schietinger, an associate member of the Immunology Program...
KU Medical Center Researchers Receive R01 Grant From NCI to Improve Access to Targeted Cancer Treatments for Rural Patients
Precision medicine has revolutionized cancer treatment—but only for patients who have access to treatments. Nearly 2 million people in the United States are diagnosed each year with cancer, but access to targeted treatments varies widely, and only about half of the eligible people receive them,...
The Influence of Structural Racism and Poverty on Outcomes in Leukemia
In the United States, Black American patients with acute myeloid leukemia (AML) have notably worse survival outcomes compared to White patients. In addition, Black patients are less likely to receive intensive chemotherapy and undergo allogeneic stem cell transplants. Many researchers have reported ...
How Experts Treat Mantle Cell Lymphoma in First Complete Response
Options are growing in the treatment of mantle cell lymphoma after complete response. At the 2022 Pan Pacific Lymphoma Conference,1 the use of these newer strategies in older patients was discussed by Brad S. Kahl, MD, Professor of Medicine and Director of the Lymphoma Service at Washington...
Determining the Role of Muscadine Grape Skin Extract in Treating Prostate Cancer
Oxidative stress is a key factor in the development of many diseases including cancer. Antioxidants prevent cellular damage by neutralizing free radicals and are being investigated as potential therapeutic strategies against cancer. In this installment of The ASCO Post’s Integrative Oncology...
Phase III NORA Trial: Niraparib Maintenance Shows Overall Survival Trend in Platinum-Sensitive Recurrent Ovarian Cancer
Maintenance therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor may do more than just delay disease progression for patients with platinum-sensitive, relapsed ovarian cancer; it might also improve overall survival, according to data presented during the December 2022 European Society for...
